Nanoformulations in the treatment of lung cancer: current status and clinical potential.

IF 2.4 4区 医学 Q3 CHEMISTRY, MEDICINAL Drug Development and Industrial Pharmacy Pub Date : 2024-12-11 DOI:10.1080/03639045.2024.2437562
Mahmoud A Younis, Mohammad A Alsogaihi, Ahmed A H Abdellatif, Imran Saleem
{"title":"Nanoformulations in the treatment of lung cancer: current status and clinical potential.","authors":"Mahmoud A Younis, Mohammad A Alsogaihi, Ahmed A H Abdellatif, Imran Saleem","doi":"10.1080/03639045.2024.2437562","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Recent developments in nanotechnology have regained hope in enabling the eradication of lung cancer, while overcoming the drawbacks of the classic therapeutics. Nevertheless, there are still formidable obstacles that hinder the translation of such platforms from the bench into the clinic. Herein, we shed light on the clinical potential of these formulations and discuss their future directions.</p><p><strong>Significance of review: </strong>The current article sheds light on the recent advancements in the recruitment of nanoformulations against lung cancer, focusing on their unique features, merits, and demerits. Moreover, inorganic nanoparticles, including gold, silver, magnetic, and carbon nanotubes are highlighted as emerging drug delivery technologies. Furthermore, the clinical status of these formulations is discussed, with particular attention on the challenges that they encounter in their clinical translation. Lastly, the future perspectives in this promising area are inspired.</p><p><strong>Key findings: </strong>Nanoformulations have a promising potential in improving the physico-chemical properties, pharmacokinetics, delivery efficiency, and selectivity of lung cancer therapeutics. The key challenges that encounter their clinical translation include their structural intricacy, high production cost, scale-up issues, and unclear toxicity profiles. The application of biodegradable platforms improves the biosafety of lung cancer-targeted nanomedicine. Moreover, the design of novel targeting strategies that apply a lower number of components can promote their industrial scalability and deliver them to the market at affordable prices.</p><p><strong>Conclusions: </strong>Nanomedicines have opened up new possibilities for treating lung cancer. Focusing on tackling the challenges that hinder their clinical translation will promote the future of this area of endeavor.</p>","PeriodicalId":11263,"journal":{"name":"Drug Development and Industrial Pharmacy","volume":" ","pages":"1-17"},"PeriodicalIF":2.4000,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Development and Industrial Pharmacy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/03639045.2024.2437562","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Recent developments in nanotechnology have regained hope in enabling the eradication of lung cancer, while overcoming the drawbacks of the classic therapeutics. Nevertheless, there are still formidable obstacles that hinder the translation of such platforms from the bench into the clinic. Herein, we shed light on the clinical potential of these formulations and discuss their future directions.

Significance of review: The current article sheds light on the recent advancements in the recruitment of nanoformulations against lung cancer, focusing on their unique features, merits, and demerits. Moreover, inorganic nanoparticles, including gold, silver, magnetic, and carbon nanotubes are highlighted as emerging drug delivery technologies. Furthermore, the clinical status of these formulations is discussed, with particular attention on the challenges that they encounter in their clinical translation. Lastly, the future perspectives in this promising area are inspired.

Key findings: Nanoformulations have a promising potential in improving the physico-chemical properties, pharmacokinetics, delivery efficiency, and selectivity of lung cancer therapeutics. The key challenges that encounter their clinical translation include their structural intricacy, high production cost, scale-up issues, and unclear toxicity profiles. The application of biodegradable platforms improves the biosafety of lung cancer-targeted nanomedicine. Moreover, the design of novel targeting strategies that apply a lower number of components can promote their industrial scalability and deliver them to the market at affordable prices.

Conclusions: Nanomedicines have opened up new possibilities for treating lung cancer. Focusing on tackling the challenges that hinder their clinical translation will promote the future of this area of endeavor.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
纳米制剂治疗肺癌:现状和临床潜力。
目的:纳米技术的最新发展重新燃起了根除肺癌的希望,同时克服了传统治疗方法的缺点。尽管如此,仍有巨大的障碍阻碍着这些平台从实验室到临床的转化。在此,我们阐明了这些配方的临床潜力,并讨论了它们未来的发展方向。综述的意义:本文介绍了近年来抗肺癌纳米制剂的研究进展,重点介绍了它们的特点、优点和缺点。此外,无机纳米粒子,包括金、银、磁性纳米管和碳纳米管,作为新兴的药物输送技术被强调。此外,这些配方的临床状况进行了讨论,特别关注他们在临床翻译中遇到的挑战。最后,展望了该领域的发展前景。主要发现:纳米制剂在改善肺癌治疗药物的理化性质、药代动力学、给药效率和选择性方面具有很大的潜力。其临床转化面临的主要挑战包括结构复杂性、高生产成本、规模问题和不明确的毒性特征。生物可降解平台的应用提高了肺癌靶向纳米药物的生物安全性。此外,采用较少数量组件的新颖目标策略的设计可以提高其工业可扩展性,并以可承受的价格将其交付给市场。结论:纳米药物为治疗肺癌开辟了新的可能性。专注于解决阻碍临床翻译的挑战将促进这一领域的未来。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
相关文献
Nephrography; simplified technic.
IF 19.7 1区 医学RadiologyPub Date : 1950-12-01 DOI: 10.1148/55.6.827
J VESEY, C T DOTTER, I STEINBERG
[Simplified suture technic].
IF 0 Die QuintessenzPub Date : 1970-10-01 DOI:
H Erdmann
来源期刊
CiteScore
6.80
自引率
0.00%
发文量
82
审稿时长
4.5 months
期刊介绍: The aim of Drug Development and Industrial Pharmacy is to publish novel, original, peer-reviewed research manuscripts within relevant topics and research methods related to pharmaceutical research and development, and industrial pharmacy. Research papers must be hypothesis driven and emphasize innovative breakthrough topics in pharmaceutics and drug delivery. The journal will also consider timely critical review papers.
期刊最新文献
Recent advances in ruthenium (III) complex-loaded nanomaterial for enhanced cancer therapy efficacy. Formulation, Characterization and in vitro Release of Topical Nanoemulsion Containing Prednisolone-Derived Corticosteroid. Tumor microenvironment as a target for developing anticancer hydrogels. Comparison Between Molecular Dynamics Potentials for Simulation of Graphene-Based Nanomaterials for Biomedical Applications. Optimizing voriconazole-loaded thermoresponsive hydrogel: in silico tools and ex vivo studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1